A total of @ patients ( @ % ) in the enzalutamide group , as compared with @ patients ( @ % ) in the placebo group , were alive at the data-cutoff date ( @ % reduction in the risk of death ; hazard ratio , @ ; @ % CI , @ to @ ; P < @ ) .